Global Access to Radiotherapy for Lung Cancer

At the end of this webinar, learners will be able to: 

1. Describe the current global RT capacity and identify the unique challenges for treating lung cancer with RT in LMIC. 
2. Summarize the main barriers to access RT for lung Cancer, the necessary human capacity to provide RT, and challenges to train Radiation Oncologists, Therapists, and Medical Physicians in LMICs. 
3. Describe research and innovation efforts aiming at addressing these disparities.

This webinar is designed to meet the educational needs of physicians, nurses and allied health professionals, patient advocates, and researchers specializing in palliative care, medical oncology, thoracic surgery, and radiation oncology. Early career radiation oncologists and medical oncologists with a focus on global health will also benefit from this webinar. 

Accreditation Statement
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Corinne Faivre-Finn, FRCR, MD, PhD discloses she receives research funding from Astra Zeneca, MSD Pharmaceuticals and Elekta and is on an advisory board and scientific committees for Astra Zeneca.

Pablo Muñoz-Schuffenegger, MD discloses he is on an advisory board for Astra Zeneca.

All other planners, reviewers and staff reported no relevant financial relationships.

All relevant financial relationships have been mitigated.